Cancer Research on Prevention and Treatment    2022, Vol. 49 Issue (07) : 639-643     DOI: 10.3971/j.issn.1000-8578.2022.21.1527
|
Progress on Immunotherapy of Gastrointestinal Cancer
CHEN Weichang1,2, SHI Tongguo2, ZHU Jinghan1, SUN Linqing1, LI Juntao1
1. Department of Gastroenterology, The First Affiliated Hospital of Soochow University, Suzhou 215000, China; 2. Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou 215000, China
Download: PDF(3821 KB)   ( 86 )   HTML ()
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract Gastrointestinal cancers are the common malignant tumors of the digestive system, and their morbidity and mortality are in the forefront of malignant tumors. Currently, cancer immunotherapy is the hottest topic in cancer research field. Although cancer immunotherapy has achieved some results in the fundamental research and clinical application of gastrointestinal tumors, there are still a series of problems that need to be resolved. In this article, we review the fundamental and clinical research progress of several common methods of cancer immunotherapy in the field of gastrointestinal tumors.
Keywords Gastrointestinal cancer      Immunotherapy      PD-1      Cell therapy     
ZTFLH:  R735.2  
  R735.3  
Fund:National Natural Science Foundation of China (No. 81802843, 81672372, 82073156)
Issue Date: 14 July 2022
 Cite this article:   
CHEN Weichang,SHI Tongguo,ZHU Jinghan, et al. Progress on Immunotherapy of Gastrointestinal Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 639-643.
 URL:  
http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.21.1527
http://www.zlfzyj.com/EN/Y2022/V49/I07/639
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
CHEN Weichang
SHI Tongguo
ZHU Jinghan
SUN Linqing
LI Juntao
[1] Siegel R, Miller K, Jemal A. Cancer statistics, 2020[J]. CA Cancer
J Clin, 2020, 70(1): 7-30.
[2] Cao W, Chen H, Yu Y, et al. Changing profiles of cancer burden
worldwide and in China: a secondary analysis of the global cancer
statistics 2020[J]. Chin Med J, 2021, 134(7): 783-791.
[3] Abdul-Latif M, Townsend K, Dearman C, et al. Immunotherapy
in gastrointestinal cancer: The current scenario and future
perspectives[J]. Cancer Treat Rev, 2020, 88: 102030.
[4] Wang DK, Zuo Q, He QY, et al. Targeted Immunotherapies
in Gastrointestinal Cancer: From Molecular Mechanisms to
Implications[J]. Front Immunol, 2021, 12: 705999.
[5] Kennedy LB, Salama AKS. A review of cancer immunotherapy
toxicity[J]. CA Cancer J Clin, 2020, 70(2): 86-104.
[6] Li B, Chan HL, Chen P. Immune Checkpoint Inhibitors: Basics
and Challenges[J]. Curr Med Chem, 2019, 26(17): 3009-3025.
[7] Singh S, Hassan D, Aldawsari HM, et al. Immune checkpoint
inhibitors: a promising anticancer therapy[J]. Drug Discov Today,
2020, 25(1): 223-229.
[8] Sharma P, Allison JP. The future of immune checkpoint therapy[J].
Science, 2015, 348(6230): 56-61.
[9] Chikuma S. CTLA-4, an Essential Immune-Checkpoint for T-Cell
Activation[J]. Curr Top Microbiol Immunol, 2017, 410: 99-126.
[10] Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 Checkpoint
Signaling Inhibition for Cancer Immunotherapy: Mechanism,
Combinations, and Clinical Outcome[J]. Front Pharmacol, 2017, 8: 561.
[11] André T, Shiu KK, Kim TW, et al. Pembrolizumab in
Microsatellite-Instability-High Advanced Colorectal Cancer[J]. N
Engl J Med, 2020, 383(23): 2207-2218.
[12] Overman MJ, McDermott R, Leach JL, et al. Nivolumab in
patients with metastatic DNA mismatch repair-deficient or
microsatellite instability-high colorectal cancer (CheckMate 142):
an open-label, multicentre, phase 2 study[J]. Lancet Oncol, 2017,
18(9): 1182-1191.
[13] Lenz HJ, Van Cutsem E, Luisa Limon M, et al. First-Line
Nivolumab Plus Low-Dose Ipilimumab for Microsatellite
Instability-High/Mismatch Repair-Deficient Metastatic Colorectal
Cancer: The PhaseⅡCheckMate 142 Study[J]. J Clin Oncol,
2022, 40(2): 161-170.
[14] Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with
advanced gastric or gastro-oesophageal junction cancer refractory
to, or intolerant of, at least two previous chemotherapy regimens
(ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 390(10111):
2461-2471.
[15] Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and Safety
of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs
Chemotherapy Alone for Patients With First-line, Advanced
Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized
Clinical Trial[J]. JAMA Oncol, 2020, 6(10): 1571-1580.
[16] Moehler M, Dvorkin M, Boku N, et al. Phase Ⅲ Trial of
Avelumab Maintenance After First-Line Induction Chemotherapy
Versus Continuation of Chemotherapy in Patients With Gastric
Cancers: Results From JAVELIN Gastric 100[J]. J Clin Oncol,
2021, 39(9): 966-977.
[17] Bagchi S, Yuan R, Engleman EG. Immune Checkpoint Inhibitors
for the Treatment of Cancer: Clinical Impact and Mechanisms of
Response and Resistance[J]. Annu Rev Pathol, 2021, 16: 223-249.
[18] Wang R, Ma Y, Zhan S, et al. B7-H3 promotes colorectal cancer
angiogenesis through activating the NF-kappaB pathway to induce
VEGFA expr‍ession[J]. Cell Death Dis, 2020, 11(1): 55.
[19] Shi T, Ma Y, Cao L, et al. B7-H3 promotes aerobic glycolysis and
chemoresistance in colorectal cancer cells by regulating HK2[J].
Cell Death Dis, 2019, 10(4): 308.
[20] Ma Y, Zhan S, Lu H, et al. B7-H3 regulates KIF15-activated
ERK1/2 pathway and contributes to radioresistance in colorectal
cancer[J]. Cell Death Dis, 2020, 11(10): 824.
[21] Lu H, Shi T, Wang M, et al. B7-H3 inhibits the IFN-γ-dependent
cytotoxicity of Vγ9Vδ2 T cells against colon cancer cells[J].
Oncoimmunology, 2020, 9(1): 1748991.
[22] Lu H, Ma Y, Wang M, et al. B7-H3 confers resistance to Vγ9Vδ2
T cell-mediated cytotoxicity in human colon cancer cells via the
STAT3/ULBP2 axis[J]. Cancer Immunol Immunother, 2021,
70(5): 1213-1226.
[23] Wang J, Wu H, Chen Y, et al. B7-H5 blockade enhances CD8+
T-cell-mediated antitumor immunity in colorectal cancer[J]. Cell
Death Discov, 2021, 7(1): 248.
[24] Trapani JA, Darcy PK. Immunotherapy of cancer[J]. Aust Fam
Physician, 2017, 46(4): 194-199.
[25] Davila ML, Bouhassira DC, Park JH, et al. Chimeric antigen
receptors for the adoptive T cell therapy of hematologic
malignancies[J]. Int J Hematol, 2014, 99(4): 361-371.
[26] Jiang H, Shi Z, Wang P, et al. Claudin18.2-Specific Chimeric
Antigen Receptor Engineered T Cells for the Treatment of Gastric
Cancer[J]. J Natl Cancer Inst, 2019, 111(4): 409-418.
[27] Lv J, Zhao R, Wu D, et al. Mesothelin is a target of chimeric
antigen receptor T cells for treating gastric cancer[J]. J Hematol
Oncol, 2019, 12(1):18.
[28] Wu D, Lv J, Zhao R, et al. PSCA is a target of chimeric antigen
receptor T cells in gastric cancer[J]. Biomark Res, 2020, 8: 3.
[29] Magee MS, Abraham TS, Baybutt TR, et al. Human GUCY2CTargeted
Chimeric Antigen Receptor (CAR)-Expressing T Cells
Eliminate Colorectal Cancer Metastases[J]. Cancer Immunol Res,
2018, 6(5): 509-516.
[30] Hombach AA, Rappl G, Abken H. Blocking CD30 on T Cells
by a Dual Specific CAR for CD30 and Colon Cancer Antigens
Improves the CAR T Cell Response against CD30 Tumors[J]. Mol
Ther, 2019, 27(10): 1825-1835.
[31] Hombach AA, Geumann U, Günther C, et al. IL7-IL12 Engineered
Mesenchymal Stem Cells (MSCs) Improve A CAR T Cell Attack
Against Colorectal Cancer Cells[J]. Cells, 2020, 9(4): 873.
[32] Liu L, Liu Y, Xia Y, et al. Synergistic killing effects of PDL1-
CAR T cells and colorectal cancer stem cell-dendritic cell
vaccine-sensitized T cells in ALDH1-positive colorectal cancer
stem cells[J]. J Cancer, 2021, 12(22): 6629-6639.
[33] Hege KM, Bergsland EK, Fisher GA, et al. Safety, tumor
trafficking and immunogenicity of chimeric antigen receptor
(CAR)-T cells specific for TAG-72 in colorectal cancer[J]. J
Immunother Cancer, 2017, 5: 22.
[34] 王一然, 陈铃, 湛先保. CAR-T细胞治疗消化系统肿瘤的研究
进展[J]. 中国肿瘤生物治疗杂志, 2020, 27(7): 813-819. [Wang
YR, Chen L, Zhan XB. Research progress on the CAR-T therapy
in treating gastrointestinal tumors[J]. Zhongguo Zhong Liu Sheng
Wu Zhi Liao Za Zhi, 2020, 27(7): 813-819.]
[35] Jung IH, Kim DH, Yoo DK, et al. In Vivo Study of Natural Killer
(NK) Cell Cytotoxicity Against Cholangiocarcinoma in a Nude
Mouse Model[J]. In vivo, 2018, 32(4): 771-781.
[36] Abdolahi S, Ghazvinian Z, Muhammadnejad S, et al. Adaptive
NK Cell Therapy Modulated by Anti-PD-1 Antibody in Gastric
Cancer Model[J]. Front Pharmacol, 2021, 12: 733075.
[37] Jin YY, Yang WZ, Sun ZY, et al. NK cells adjuvant therapy shows
survival benefits in a gastric mixed signet ring cell carcinoma
patient: A case report[J]. Medicine(Baltimore), 2021, 100(10): e24979.
[38] Xiao L, Cen D, Gan H, et al. Adoptive Transfer of NKG2D CAR
mRNA-Engineered Natural Killer Cells in Colorectal Cancer
Patients[J]. Mol Ther, 2019, 27(6): 1114-1125.
[39] Nayyar G, Chu Y, Cairo MS. Overcoming Resistance to Natural
Killer Cell Based Immunotherapies for Solid Tumors[J]. Front
Oncol, 2019, 9: 51.
[40] Du Y, Wei Y. Therapeutic Potential of Natural Killer Cells in
Gastric Cancer[J]. Front Immunol, 2018, 9: 3095.
[41] Girardi M. Immunosurveillance and immunoregulation by
gammadelta T cells[J]. J Invest Dermatol, 2006, 126(1): 25-31.
[42] Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape
of genes and infiltrating immune cells across human cancers[J].
Nat Med, 2015, 21(8): 938-945.
[43] Yamaguchi Y, Katata Y, Sano F, et al. Adoptive immunotherapy for
gastric cancer using zoledronate-activated killer cells: A prospective
observational study[J]. Mol Clin Oncol, 2020, 13(5): 55.
[44] Wada I, Matsushita H, Noji S, et al. Intraperitoneal injection of
in vitro expanded Vγ9Vδ2 T cells together with zoledronate for
the treatment of malignant ascites due to gastric cancer[J]. Cancer
Med, 2014, 3(2): 362-375.
[45] Li J, Sun L, Chen Y, et al. Gastric cancer-derived exosomal miR-
135b-5p impairs the function of Vγ9Vδ2 T cells by targeting
specificity protein 1[J]. Cancer Immunol Immunother, 2022,
71(2): 311-325.
[46] Kawazoe A, Fukuoka S, Nakamura Y, et al. Lenvatinib plus
pembrolizumab in patients with advanced gastric cancer in
the first-line or second-line setting (EPOC1706): an openlabel,
single-arm, phase 2 trial[J]. Lancet Oncol, 2020, 21(8):
1057-1065.
[47] Chen EX, Jonker DJ, Loree JM, et al. Effect of Combined
Immune Checkpoint Inhibition vs Best Supportive Care Alone in
Patients With Advanced Colorectal Cancer: The Canadian Cancer
Trials Group CO.26 Study[J]. JAMA Oncol, 2020, 6(6): 831-838.
[48] Winer A, Ghatalia P, Bubes N, et al. Dual Checkpoint Inhibition
with Ipilimumab plus Nivolumab After Progression on Sequential
PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a
Patient with Lynch Syndrome, Metastatic Colon, and Localized
Urothelial Cancer[J]. Oncologist, 2019, 24(11): 1416-1419.
Related articles from Frontiers Journals
[1] YANG Junyuan, CAI Hongbing. Countermeasures and Mechanisms of Drug Resistance in Immunotherapy for Cervical Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 886-892.
[2] CHANG Jinyi, WANG Wei, CAI Haifeng. Research Progress of PD-1/PD-L1 Inhibitor Combined with Trastuzumab in HER2-positive Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 965-969.
[3] YIN Zhucheng, LIANG Xinjun. Research Progress on Combined Immunotherapy for Microsatellite Stable Colorectal Cancer#br#[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 977-981.
[4] CAO Guangwen. Theoretical Update of Cancer Evo-Dev and Its Role in Targeted Immunotherapy for Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 747-755.
[5] KANG Yikun, YUAN Peng. Advances in Treatment of Triple Negative Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 812-819.
[6] YIN Zhucheng, LIANG Xinjun. Research Progress on Hyperthermia and Anti-Tumor Immunity[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 827-831.
[7] XIA Siyu, ZHAO Zitong, LI Li. Correlation Between STK11 Gene Mutation and Immunotherapy of Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 850-854.
[8] JIN Tongtong, ZHOU Chuan, WANG Chao, DA Zijian, ZHOU Fenghai, . Research Hotspots and Frontiers of Immunotherapy for Prostate Cancer: A Visual Analysis[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 667-674.
[9] WU Wei, JING Doudou, CAO Li, PU Feifei, SHAO Zengwu. Current Status and Prospects of Immunotherapy for Osteosarcoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 721-726.
[10] CHEN Bojin, HU Xingyi, ZHAO Jingwen, ZHENG Aihong. Current Status of Immunotherapy in Neoadjuvant Therapy for Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 727-732.
[11] ZHANG Jianning, LIU Congwei. Progress of Novel Treatment Options for Glioma[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 505-513.
[12] SUN Junzhao, CHENG Gang, ZHANG Jianning. Advances in Treatment of Brain Metastasis from Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 522-527.
[13] ZHANG Yu, HE Kunyu, FENG Shiyu. Current Progress in Treatment of Glioma[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 528-534.
[14] LI Yuxin, JIN Feng, . Immune Checkpoint PD-1-based Mechanisms of Tumor Immune Resistance and Strategies for Re-treatment After Drug Resistance[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 546-551.
[15] HOU Jian, WANG Junying. Research Progress of Immune Microenvironment in Multiple Myeloma[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 375-378.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed